← Eichor
Condition: Rectal Cancer Stage Ii Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Rectal Cancer Stage Ii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07448142A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05672524ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer
Phase N/A · 1 location(s) · Gene Solutions · NCT06589388Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Phase 1 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT04703101Efficacy and Toxicity of Total Neoadjuvant Sandwich Treatment Via Short Course Radiotherapy in the Treatment of Stage II
Phase 2 · 1 location(s) · Ain Shams University · NCT07095439Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cance
Phase 3 · 1 location(s) · Fudan University · NCT05954078The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
Phase 2 · 1 location(s) · Fudan University · NCT05628038A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally
Phase 2/Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07454720Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06834126Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT07176182Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treat
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07047560Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
NA · 2 location(s) · University of California, San Francisco · NCT042218935-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
Phase 2 · 1 location(s) · The Methodist Hospital Research Institute · NCT06887218A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer
Phase 2 · 1 location(s) · First Affiliated Hospital of Wenzhou Medical University · NCT07347951Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Phase 2 · 4 location(s) · Dustin Deming · NCT06493019MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer
NA · 1 location(s) · Sun Yat-sen University · NCT06204484Family Communications After Genetic Testing
NA · 276 location(s) · Alliance for Clinical Trials in Oncology · NCT07143487Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
Phase 2/Phase 3 · 16 location(s) · Centre Hospitalier Universitaire de Besancon · NCT05462613SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06850103GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06558773XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05970302PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsa
Phase 3 · 1 location(s) · Centre Hospitalier Universitaire Dijon · NCT06762405SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT06767007Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
Phase 2 · 1 location(s) · National Cancer Centre, Singapore · NCT04912765Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
NA · 1 location(s) · Fred Hutchinson Cancer Center · NCT06802172OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
Phase 2 · 2 location(s) · Karen-Lise Garm Spindler · NCT04680260The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
Phase N/A · 1 location(s) · Case Comprehensive Cancer Center · NCT04624555Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Phase 1/Phase 2 · 87 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT04930432Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Meta
Phase 2 · 1 location(s) · Dominik Paul Modest · NCT05007132
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.